Canagliflozin Targeting Vascular Inflammation: an Ottawa Imaging Study - a Pilot Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 1\) Stable CAD (over 60 days post-myocardial infarction).
• 2\) Diabetes
• 3\) given informed consent.
Locations
Other Locations
Canada
University of Ottawa Heart Institute
RECRUITING
Ottawa
Contact Information
Primary
Kevin Boczar, MD
kboczar@ottawaheart.ca
613 696 7000
Time Frame
Start Date: 2024-11-15
Estimated Completion Date: 2026-12
Participants
Target number of participants: 24
Treatments
Active_comparator: Active
Canagliflozin 300mg PO daily
Placebo_comparator: Placebo
Placebo PO daily
Authors
Related Therapeutic Areas
Sponsors
Leads: Ottawa Heart Institute Research Corporation